Gujarat Themis Biosyn will convene an Extraordinary General Meeting (EGM) on Saturday, August 22, 2026, at 12:00 pm at the registered office of Themis Medicare Limited in Vapi, Gujarat. The primary objective is to secure shareholder approval for significant related party transactions, including borrowing up to ₹450 crore and obtaining guarantees worth up to ₹1,000 crore from promoter group entities. These funds are intended to support strategic acquisitions, investments in subsidiaries, and working capital augmentation, providing the company with financial flexibility to execute its growth strategy without sole reliance on external financing.

The proposed transactions involve Dr. Sachin D. Patel, Managing Director and Promoter, along with Pharmaceutical Business Group India Limited (PBGIL) and Themis Medicare Limited (TML), both promoter group companies. Under the Companies Act, 2013, and SEBI Listing Regulations, these transactions qualify as material related party transactions due to their scale relative to the company’s turnover. The Audit Committee and the Board of Directors have reviewed and approved the terms, which include commercially reasonable interest rates benchmarked against prevailing market rates for similar borrowings. The borrowings are unsecured, though security may be mutually agreed upon.

Key Transaction Details

In addition to the funding approvals, shareholders will vote on a special resolution to amend Article 13(1)(c) of the Articles of Association. The amendment removes the mandatory requirement for a registered valuer’s report for all further issues of share capital, aligning the company’s internal governance with the current statutory framework under the Companies Act, 2013 and SEBI regulations. This change aims to streamline future equity issuances where valuation reports are not legally mandated.

Debt Securities Authorization

The EGM will also consider a special resolution authorizing the private placement of Non-Convertible Debentures (NCDs) and other debt securities. The Board seeks an enabling resolution to issue debt instruments with an outstanding principal amount not exceeding ₹1,500 crore. This authorization allows the company to diversify its debt portfolio and access competitive borrowing sources through private placements to eligible investors, including mutual funds, banks, and institutional buyers. The Board retains discretion to determine terms, pricing, and listing arrangements based on prevailing market conditions.

What the Numbers Show

The scale of the proposed related party transactions is significant relative to the company’s recent financial performance. The proposed borrowing of ₹450 crore represents approximately 271% of the listed entity’s annual standalone turnover for the preceding financial year. Similarly, the proposed guarantee of ₹1,000 crore equates to 603% of that turnover. For context, PBGIL reported a standalone turnover of ₹2.57 crore in FY25, while TML reported ₹342.24 crore. The heavy reliance on promoter group funding underscores the company’s aggressive expansion phase, particularly in strategic acquisitions, which may not yet be fully supported by internal cash flows or traditional banking channels. Shareholders should note that existing borrowings from these entities were nil in FY25, indicating this is a new line of credit rather than a renewal.

Voting and Logistics

Remote e-voting will be available from August 19, 2026, at 9:00 am to August 21, 2026, at 5:00 pm, via the Central Depository Services Limited (CDSL) platform. The cut-off date for voting eligibility is Saturday, August 15, 2026. Shareholders holding shares as on this date can cast their votes electronically. Physical attendance is also permitted at the Vapi venue for those who have not voted remotely. The scrutinizer for the process is Mr. Ketan R. Shirwadkar of M/s. KRS AND CO., Practicing Company Secretaries.

Gujarat Themis Biosyn has announced that its board of directors is scheduled to meet on August 7 to review the company's financial results for the first quarter (Q1).

Board Meeting Details

The upcoming board meeting represents a key event for investors and market participants tracking the company's financial performance. The following details have been disclosed regarding the scheduled review:

What to Watch

Stakeholders and investors are expected to closely monitor the outcome of the board meeting, as the Q1 results will provide insight into the company's financial performance for the quarter. No additional financial data or metrics have been made available ahead of the scheduled review date.